2. Radisson Blu Hotel, London Stansted - Tuesday 24th June 2014
3
Welcome To The ACEA Biosciences
xCELLigence User Group Meeting
Dear Researcher,
On behalf of Cambridge Bioscience and ACEA Biosciences, it gives us
great pleasure to welcome you to our second xCELLigence User Group
Meeting at the Radisson Blu Hotel in London Stansted. The goal of this
meeting is to ensure that you are updated with the latest information
on the xCELLigence technology, as well as giving you the opportunity to
share your experiences of using the xCELLigence real-time, impedance-
based systems with other experts in the field.
This year’s meeting has brought together leading scientists working
in a variety of research areas, where the xCELLigence technology has
been an integral part of their work. The use of impedance based cell
analysis is widely accepted in application areas from cell invasion and
migration through to GPCR and cardiotoxicity, with over 500 peer
reviewed publications citing the xCELLigence system. However, we also
want to look to the future and have some cutting edge speakers who
will address a range of emerging research areas, capitalizing on the use
of label free real-time cellular analysis now available – research that will
help improve the progression of drug screening programs in the search
for viable drug candidates and thus reduce late stage new drug attrition
rates.
Needless to say, our success has been built upon valuable feedback from
researchers like yourselves and we appreciate and value your continued
feedback. I hope that this user meeting will, therefore, be of benefit to
you, to give you the opportunity to exchange experiences, and enable
us to meet your needs more closely in the future. We would therefore
like to thank you for your attendance at this meeting and hope you
enjoy the day.
Jay Champaneri
Senior Business Manager
Cambridge Bioscience Instruments Division
Tel: 01223 316 855 ext. 209
Email: jay.champaneri@bioscience.co.uk
0
2
4
6
8
10
0 20 40 60 80
100
NormalizedCellIndex
Time (Hours)
MG132 5-FU No Cpd
Cell Proliferation and Cytotoxicity
Cpd Addition
A549
0.8
1.0
1.2
1.4
1.6
0 10 20 30
NormalizedCellIndex
Time (Minutes)
50 µM
16.7 µM
5.56 µM
1.85 µM
617 nM
206 nM
69 nM
0
Functional Monitoring of Receptor Signaling
Hela
Histamine
Cell Adhesion and Spreading
0
0.2
0.4
0.6
0.8
1
1.2
1.4
0 0.4 0.8 1.2 1.6 2
CellIndex
Time (Hours)
A549 Collagen IV
10 µg/mL
5 µg/mL
2.5 µg/mL
0 µg/mL
To find out more please visit www.bioscience.co.uk/icelligence
Wireless label-free real-time
cell-based assays
Automatic quantitative assessment of
cell adhesion, proliferation, cytotoxicity
& receptor response
Real time monitoring of cell responses
for the entire experiment
Kinetic information shows optimal
time point for compound addition
during experiment
The iCELLigence™ System
Capture Biology As It Happens
3. ACEA xCELLigence User Group Meeting
4
Radisson Blu Hotel, London Stansted - Tuesday 24th June 2014
5
1:45pm - 2:15pm Investigating TGFß driven breast cancer invasion
& migration using xCELLigence
Dr Gareth J. Inman
Reader & Group Leader, Division of Cancer
Research, University of Dundee
2:15pm - 2:45pm Using the biology of ageing to optimise
therapeutic chemistry
Prof Paul Shiels
Professor of Cellular Gerontology,
University of Glasgow
2:45pm - 3:15pm The use of label-free electrical impedance sensing
technologies to investigate G-protein coupled
receptor signalling & chemotaxis in both primary
murine macrophages & transfected cell lines
Dr Asif Iqbal
Post-Doc Research Scientist, University of Oxford
3:15pm - 3:45pm Coffee break
3:45pm - 4:15pm Use of xCELLigence technology in
characterisation of endocrine resistant breast
cancer cell lines
Dr Monica Faronato
Research Technician, Imperial College London
4:15pm - 4:30pm Labcare – an effective & professional technical
service partner for Cambridge Bioscience
Mr Philip Sandom
Managing Director, Labcare Service Ltd
4:30pm - 4:45pm Q & A discussion
Chair - Dr Patrick Kiely
4:45pm Closing remarks
Jay Champaneri
Business Manager, Cambridge Bioscience
Agenda
Tuesday 24th June
9:30am - 10:00am Registration opens & coffee
10:00am - 10:05am Opening remarks
Jay Champaneri
Business Manager, Cambridge Bioscience
10:05am - 10:35am The latest news from ACEA Biosciences
Dr Yama Abassi
Vice President, ACEA Biosciences
10:35am - 11:15am Using real-time cell analysis to monitor the
transformed phenotype in cancer
Dr Patrick Kiely
Lecturer & Principal Investigator of the Laboratory
of Cellular & Molecular Biology, University of
Limerick
11:15am - 11:35am Coffee break
11:35am - 12:05pm Use of iCELLigence platform in process
development & QC testing for clinical
manufacture of a cellular therapy product
Dr Gary Brooke
Manufacturing Project Manager, ReNeuron Ltd
12:05pm - 12:35pm Evaluation of cardiac dysrhythmia of oncology
therapeutics using xCELLigence technologies
Prof Jason Gill
Reader in Molecular Therapeutics,
University of Durham
12:35pm - 12:50pm Real-time analyses of human vascular smooth
muscle contraction & endothelial cell adhesion &
proliferation using bioimpedance
Dr Richard Siow
Senior Lecturer, Cardiovascular Division, School
of Medicine, King’s College London
12:50pm - 1:45pm Lunch
4. ACEA xCELLigence User Group Meeting
6
Radisson Blu Hotel, London Stansted - Tuesday 24th June 2014
7
MCF7-FULVR) or oestrogen deprivation (LTED). LTED-TAMR and LTED-
FULVR were derived from LTED exposed to Tamoxifen or Fulvestrant
respectively. Hence, these panel of cells mimic tumours resistance to all
conditions, where oestrogen is still present.
Motility and invasion are hallmarks of cancer. Our objective is to
explore the effects of drug resistance on these key events in cancer.
Our initial findings demonstrate phenotypical difference amongst those
models. MCF7 and MCF7 derived cells display poor migratory and
invasive capacity, which is increased in LTED and LTED derived cells. The
absence of oestrogen (AI resistance) seems to be a key player for cells
to undergo epithelial to mesenchymal transition (EMT) and becoming
more aggressive. Interestingly, the most aggressive cells (LTED-FULVR)
were also the ones with the slower proliferation rate. The xCELLigence
technology has enabled real time characterization of these cells in a
more effective and less time consuming way compared to the standard
chamber based assay. We are now on the way to further characterise ET
resistance using these models.
Evaluation of cardiac dysrhythmia of oncology therapeutics using
xCELLigence technologies
Prof Jason Gill; Reader in Molecular Therapeutics, University of Durham
Many cancer therapeutics have shown promise during drug
development, with several now demonstrating success in the clinic.
However, an increasing number of these agents have either not made
it to the clinic, or have demonstrated toxicities upon the cardiac system
when they enter the clinic. Consequently, there is a high attrition rate
for the clinical development of these agents. Furthermore, cardiac
complications several years post-treatment are now a major issue
which impact upon patient survival and quality of life. A significant
issue is that the identification of adverse cardiac events with cancer
chemotherapeutics is often not identified until late stage development
or the clinic. This is further complicated by the current evaluation of
these agents as monotherapies rather than as part of clinically relevant
multiagent therapies, with subsequent implications for cardiotoxicity.
Therefore there is a need for improved screening methodologies
with greater predictabilities and clinical relevance for identification of
cardiac liabilities of cancer chemotherapeutics. The ability to create
cardiomyocytes from induced pluripotent stem cells, and their ability to
form a functional syncytium which spontaneously and synchronously
beats in vitro has opened up the ability to evaluate cardiac safety
potential of chemotherapeutics in vitro. In our group, we are using
in vitro models of both mouse and human induced pluripotent stem
cell derived cardiomyocytes, and the impedance based xCELLigence
cardio analysis platform to determine the cardiotoxic and proarrhythmic
potential of cancer therapeutics. This system permits continuous real-
time non-labelled monitoring of contractility and drug effects, allowing
direct measurement of pharmaco- and toxicodynamic effects. A
major objective is to develop a ‘clear line of sight’ for identification of
cardiotoxic potential from in vitro, to in vivo, and ultimately the clinic
Presentation Abstracts
The latest news from ACEA Biosciences
Dr Yama Abassi; Vice President, ACEA Biosciences
ACEA Biosciences continues on its mission to bring new and
innovative products to the cell analysis market. We will discuss the
latest developments in the global marketing of the xCELLigence and
iCELLigence systems and also officially inform our esteemed users in UK
and Ireland about our latest products and applications. Importantly, we
look forward to informing everyone about our grant programs as well as
travel awards.
Use of iCELLigence platform in process development & QC testing for
clinical manufacture of a cellular therapy product
Dr Gary Brooke; Manufacturing Project Manager, ReNeuron Ltd
ReNeuron is a leading, clinical-stage stem cell business. Its primary
objective is the development of novel stem cell therapies targeting
areas of significant unmet or poorly met medical need. ReNeuron has
used its unique stem cell technologies to develop cell-based therapies
for disease conditions where cells can be readily administered “off-
the-shelf” to any eligible patient without the need for additional
immunosuppressive drug treatments. ReNeuron’s lead candidate is its
ReN001 stem cell therapy for the treatment of patients left disabled
by the effects of a stroke. This therapy is currently in phase II clinical
development. The Company is also developing stem cell therapies for
other conditions such as critical limb ischaemia, a serious and common
side-effect of diabetes, and blindness-causing diseases of the retina such
as retinitis pigmentosa. ReNeuron require a rapid adherence/growth
assay that can be used in both development and as a quality indicator of
raw materials and/or manufactured cell banks. Here, data is presented
that show how data generated can be used to cover these needs.
Use of xCELLigence technology in characterisation of endocrine resistant
breast cancer cell lines
Dr Monica Faronato; Research Technician, Imperial College London
Breast cancer is the most common cancer in the UK. Around 50,000
people are diagnosed each year (CRUK). Several subtypes have been
described so far based on gene expression: basal (Triple negative), HER-2
Over-expression, Luminal A and B. Luminal subtypes (of which luminal B
is more aggressive) account for the majority of all the breast cancers and
express the Estrogen Receptor (ER+). Patients affected by ER+ tumours,
benefit from hormonal therapy (ET), including Aromatase Inhibitors,
oestrogen modulators (Tamoxifen), or oestrogen downregulators
(Fulvestrant). Nevertheless, 40% of ER+ patients progress despite therapy.
In our studies, we employ six different cell lines, derived from MCF7,
a cell line responsive to all Endocrine Therapies (ET). MCF7 cells were
exposed for 1year either to Tamoxifen or Fulvestrant (MCF7-TAMR and
5. ACEA xCELLigence User Group Meeting
8
Radisson Blu Hotel, London Stansted - Tuesday 24th June 2014
9
Using real-time cell analysis to monitor the transformed phenotype in
cancer
Dr Patrick Kiely; Lecturer & Principal Investigator of the Laboratory of
Cellular & Molecular Biology, University of Limerick
Increasing our knowledge of the mechanisms regulating cell adhesion,
cell proliferation and cell migration are central to our understanding
of normal and diseased cell function. These events are orchestrated
by a series of complex signalling cascades which require crosstalk
between cell surface receptors and components of the cell cytoskeleton.
In cancer, the local tumour microenvironment contributes to the
transformed phenotype by providing specific environmental cues that
alter the cells behaviour and promotes metastasis. Fibroblasts have a
strong association with cancer and in recent times there has been some
emphasis in designing novel therapeutic strategies that alter fibroblast
behaviour in the tumour microenvironment. Fibroblasts produce
growth factors, chemokines and many of the proteins laid down in
the extracellular matrix that promote angiogenesis, inflammation
and tumour progression. We use label free Real-Time Cell Analysis
platforms (xCELLigence) to investigate how media derived from human
fibroblasts alters cancer cell behaviour. As well as this, we are using the
xCELLigence CIM-plates function to decipher the signalling pathways
regulating the migration and invasion of cancer cells through matrigel
layers. Our results indicate that the stromal environment has the ability
to increase the migratory and invasive properties of cancer cells.
Labcare – an effective & professional technical service partner for
Cambridge Bioscience
Mr Philip Sandom; Managing Director, Labcare Service Ltd
From initial delivery to end of life cycle, the investment made by
xCELLigence users deserves to be protected enabling them to have
absolute confidence that it represents good value for money and a
reliable instrument representing an invaluable part of their research.
Labcare will address how the user can work with Labcare through
Cambridge Bioscience to maximise the efficiency if their instrument by
good housekeeping and regular preventative maintenance. Also we will
demonstrate the value of investing in a service contract and how that
invest can return excellent dividends on the life cycle of your instrument.
Investigating TGFß driven breast cancer invasion & migration using
xCELLigence
Dr Gareth J. Inman; Reader & Group Leader, Division of Cancer
Research, University of Dundee
Transforming growth factor beta 1 (TGFß) is the prototypical member
of a superfamily comprising approximately forty related dimeric
polypeptide cytokines. These growth factors play fundamental roles
during mammalian development and act as homeostatic factors in adult
life regulating tissue repair, wound healing and the immune response.
As well as having vital normal physiological functions these factors
play pivotal roles in disease pathogenesis including cancer progression.
Paradoxically TGFß can act as both a potent tumour suppressor and
tumour promoter in a context dependent manner. TGFß is a potent and
widespread inhibitor of cell growth and resistance to TGFß mediated
cytostasis may represent one of the fundamental hallmarks of cancer.
In contrast, there is strong evidence that TGFß-induced pro-oncogenic
effects are a common feature of advanced malignancies. TGFß can
promote tumourigenesis via a combination of tumour cell autonomous
and non-tumour-cell autonomous effects. These include regulation of
cancer stem cells (CSC), promotion of tumour cell proliferation, survival,
motility, invasion, intravasation and extravasation at distant metastatic
sites, promotion of angiogenesis and inhibition of the anti-tumour
immune response. The pro-oncogenic activities of TGFß are particularly
apparent in breast cancer whereby TGFß can promote epithelial to
mesenchymal transition (EMT), migration, invasion and metastatic
spread. We are using xCELLigence technology to dissect the kinetics and
mechanisms of TGFß mediated promotion of cell migration and invasion
with the intention of identifying key players in metastatic spread and
new potential therapeutic targets.
The use of label-free electrical impedance sensing technologies to
investigate G-protein coupled receptor signalling & chemotaxis in both
primary murine macrophages & transfected cell lines
Dr Asif Iqbal; Post-Doc Research Scientist, University of Oxford
The directional migration and subsequent adhesion of macrophages is
crucial to the clearance of pathogens and the initiation of inflammation.
Chemokines direct this migration by binding to their cognate G-protein
coupled receptors (GPCRs) and inducing cytoskeletal rearrangement.
Conventional chemotaxis systems such as the modified Boyden
chamber are limited in terms of the data captured given that the
assays are analysed at a single time-point. We report the optimisation
and validation of a label-free, real-time cell migration/signalling assay
based on electrical cell impedance to measure chemotaxis of different
primary murine macrophage populations in response to a range of CC
chemokines and other chemoattractant signalling molecules. We clearly
demonstrate key differences in the migratory behavior of different
murine macrophage populations and show that this dynamic system
measures true macrophage chemotaxis rather than chemokinesis or
fugetaxis. We highlight an absolute requirement for Gαi signaling and
actin cytoskeletal rearrangement as demonstrated by Pertussis toxin and
cytochalasin D inhibition.
6. ACEA xCELLigence User Group Meeting
10
Using the biology of ageing to optimise therapeutic chemistry
Prof Paul Shiels; Professor of Cellular Gerontology, University of Glasgow
We have employed biomarkers of cellular ageing to rank therapeutic
structurally related mTOR inhibitors, based on their effects on biological
ageing, independently of their mode of action and efficacy. Specifically,
we have used xCELLigence based analyses to determine the maximum
stoichiometric dose for each compound, that primary human cells could
withstand without affecting growth. Furthermore, ranking was based
upon the compounds ability, when applied at maximal stoichiometric
doses, to protect primary human cells from acute oxidative insult.
The top ranked compound displayed a superior in vitro cellular
protective profile, as demonstrated by eliciting a reduction in
transcriptional expression of CDKN2A. The cellular protective effect of
this compound was subsequently examined in an in vivo rodent model
of ischaemia reperfusion injury (IRI) to determine if it would translate to
protection of kidney function. In keeping with the xCELLigence data, the
top ranked compound reduced expression levels of p16ink4a and p21,
cognate proteins for CDKN2A and CDKN1A respectively, confirming a
translation of the biological chemistry approach to accurately predict
protective effects in organs in vivo. The utility of such an in vitro screen
has far-reaching potential and could be utilized to provide an early
indication of biological efficacy related to compound structure. These
data may furthermore point towards a potential protective effect of
such compounds in preventing IRI clinically.
Real-time analyses of human vascular smooth muscle contraction &
endothelial cell adhesion & proliferation using bioimpedance
Richard C Siow, Tom P Keeley, Li Li & Giovanni E Mann; BHF Centre
for Research Excellence, Cardiovascular Division, School of Medicine,
King’s College London
Changes in smooth muscle contraction during vascular diseases can
lead to a reduction of lumen diameter and remodelling of arteries.
Endothelial dysfunction contributes to vascular inflammation and
hypertension. We have used the iCELLigence (ACEA) bioimpedance
platform to provide a real time analyses of smooth muscle cell
contraction in response to various agonists and endothelial cell
adhesion and proliferation on different substrates. Our data supports
the literature to demonstrate the versatility of ACEA bioimpedance
platforms for real time assessment of endothelial and smooth muscle
cell biology to investigate the mechanisms of nomal vascular cell
function and in models of disease processes.
The xCELLigence RTCA DP System
Ever wonder if you are using the right time point?
Dynamic real-time, label-free, non-invasive cell monitoring that enables discovery not possible with end-point analysis
Increased Flexibility.
Complete Data.
More Insight.
E-Plate 16: Cellular Assay in a 16-Well Format
Quantitatively monitor the following assays in real-time:
Cell Adhesion
Compound- and cell-mediated cytotoxicity
Cell proliferation and differentiation
GPCR and RTK mediated signaling
E-Plate View 16: Visualize Cells With Ease
Use a modified version of the E-plate 16 for inspection
of cells using microscopes
CIM-Plate 16: Quantitative Cell Invasion/
Migration (CIM) Analysis
Identify optimal migration and invasion time points
Eliminate time-consuming manual detection
Perform CIM analysis in a convenient one-well-system
E-Plate Insert 16: Co-Culture in Real-Time
Continuously monitor indirect cell-cell interactions
under physiological conditions
The CIM-plate features two separable
sections for ease of experimental
setup. Cells seeded in the upper
chamber move through the
microporous membrane into the
lower chamber that contains a
chemoattractant. Cells adhering to
the microelectrode sensors lead to an
increase in impedance, which is
measured in real-time by the RTCA
DP Instrument.
Learn more about the enabling
technology of the xCELLigence
System and its broad range of
applications at
www.bioscience.co.uk/xcelligencedp
Invasion/Migration Analysis in CIM-Plates
Example of data obtained
using the CIM-Plates.
HT1080 cells (2 x 104) were
seeded in the upper
chamber of CIM-Plate
wells coated with varying
dilutions of Matrigel, or in
wells with no coating.
Serum was added to the
lower chamber of selected
wells as a chemoattractant.
Invasion was observed and
migration monitored
continuously over a
70-hour period.The serum-
free samples resulted in
baseline Cell Index levels,
while those wells with
chemoattractant induced
invasion/migration that
was delayed in proportion
to matrigel density.
An Overview of the CIM-Plate Technology
7. ACEA xCELLigence User Group Meeting
12
Radisson Blu Hotel, London Stansted - Tuesday 24th June 2014
13
Dr Monica Faronato
Use of xCELLigence technology in characterisation of endocrine resistant
breast cancer cell lines
Research Technician, Imperial College London
I completed my PhD studies in Italy in Oncology Urology where I
linked 5-Liposxygenase with the progression of Clear Cell renal cell
carcinoma. I subsequently moved to Liverpool University as a Research
Associate, where I explored the use of deubiquitinating enzymes (DUBs)
as anticancer drugs and linked the role of USP15 to the transcription
factor REST in lung cancer. I am currently working at Imperial College
in London, where I focus on breast cancer. I am interested in Endocrine
therapy Resistance and the mechanisms that underline tumour
recurrence.
Prof Jason Gill
Evaluation of cardiac dysrhythmia of oncology therapeutics using
xCELLigence technologies
Reader in Molecular Therapeutics, University of Durham
Dr Jason Gill is a Reader in Molecular Therapeutics within the Division of
Pharmacy in the School of Medicine, Pharmacy and Health. He gained
his PhD in the field of Molecular Toxicology from the University of
Manchester, and has worked for the past 15 years in the area of cancer
drug development, resulting in several patents and spin-out of a drug
company, Incanthera, to progress these agents to the clinic. He moved
to the new School of Pharmacy at Durham University in 2012, wherein
he is works in the areas of preclinical safety assessment of cancer
therapeutics and anticancer drug discovery, particularly identification
and development of tumour-selective cancer therapeutics with reduced
systemic toxicity.
Dr Gareth J. Inman
Investigating TGFß driven breast cancer invasion & migration using
xCELLigence
Reader & Group Leader, Division of Cancer Research,
University of Dundee
Gareth graduated with first class honours from The University of York.
He carried out his PhD studies on Epstein Barr virus in Professor Paul
Farrell’s laboratory in the Ludwig Institute for Cancer Research in St
Mary’s Hospital, London, before joining Professor Ed Ziff’s laboratory as
an HHMI postdoctoral fellow in New York. Gareth then returned to the
Ludwig Institute as a Wellcome Trust postdoctoral fellow and studied
TGFß signalling in human B cells in Professor Martin Allday’s lab. He
then moved to Dr Caroline Hill’s lab at the Imperial Cancer Research
Fund to study TGFß signalling dynamics. Gareth set up his own lab
investigating TGFß signalling in cancer at The Beatson Institute for
Cancer Research in Glasgow in 2003 following his award of the first
AICR International Cancer Fellowship. Gareth took up his readership
in Dundee in 2010. Work in his lab is supported by the AICR, Cancer
Research UK, Tenovus Scotland, The Anonymous Trust and the MRI.
Speaker Biographies
Dr Yama Abassi
The latest news from ACEA Biosciences
Vice President, ACEA Biosciences
Dr. Yama A. Abassi is Senior Scientific Director and VP at ACEA
Biosciences. Dr. Abassi received his undergraduate degree in
biochemistry with Honors from State University of New York/Stony
Brook in May of 1992 and a PhD degree in Molecular, Cell and
Developmental Biology from University of California at Santa Barbara
in 1999. Dr. Abassi joined the Burnham Institute for Cancer Research,
as an NIH Post-Doctoral fellow in 1999 and performed his postdoctoral
work in delineating oncogene signaling pathways and its role in cancer
biology. Dr. Abassi joined ACEA Biosciences in 2003 and has numerous
publications and patents in the application of impedance technology for
cancer research, GPCR signaling, immune function, drug discovery and
toxicity. Dr. Abassi is currently engaged in scientific collaborations using
impedance technology with government institutions such as US EPA and
also with different pharmaceutical companies. Dr. Abassi’s current role is
to oversee the global operations of ACEA Biosciences.
Dr Gary Brooke
Use Of iCELLigence platform in process development & QC testing for
clinical manufacture of a cellular therapy product
Manufacturing Project Manager, ReNeuron Ltd
Dr Gary Brooke is Project Manager for Cell Manufacturing at ReNeuron
where he has worked since joining the company in 2010. Since
completing his PhD in Immunology, Gary’s core research interests have
been in immunology and stem cell biology, working first as a post-
doc at the University of Oxford, UK and then with Mater Medical
Research Institute, Brisbane, Australia. This included the design and
development of a placental-derived mesenchymal stem/stromal cell
(MSC) manufacturing process for clinical trials. He is currently project
managing the various manufacturing operations of ReNeuron’s lead cell
lines to phase I and II clinical trials for the treatment of ischaemic stroke
and critical limb ischaemia. He also manages development activities
associated with the manufacture of ReNeuron’s cell lines.
8. ACEA xCELLigence User Group Meeting
14
Radisson Blu Hotel, London Stansted - Tuesday 24th June 2014
15
Prof Paul Shiels
Using the biology of ageing to optimise therapeutic chemistry
Professor of Cellular Gerontology, University of Glasgow
Paul Shiels is the Professor of Cellular Gerontology at the University
of Glasgow. Paul graduated from Trinity College Dublin in Natural
Sciences, following which he undertook a PhD at the University
Glasgow, where he was among the first internationally, to clone and
analyse telomeres and developed one of the first rat genomic mapping
panels. Subsequently, at PPL Therapeutics, Roslin, he helped develop
the internationally recognised Xenotransplantation programme and
undertook the analysis of senescence in cloned animals, including Dolly
the sheep.
He has also identified CDKN2A as the first validated biomarker of
ageing and has been instrumental in demonstrating the role of
biological ageing in determining transplant efficacy, which is currently
being translated clinically. Notably, Paul is part of a number of National
and International consortiums looking at psychological, sociological
and biological determinants of ageing, with special reference to what
determines healthy ageing. He has helped demonstrate that the basis of
health disparities in Glasgow has underlying epigenetic and accelerated
ageing components Paul also acts as CSA for Pathfinder Cell Therapy
PLC and sits on the Advisory Board for TC Biopharm.
Dr Richard Siow
Real-Time Analyses Of Human Vascular Smooth Muscle Contraction &
Endothelial Cell Adhesion & Proliferation Using Bioimpedance
Senior Lecturer, Cardiovascular Division, School of Medicine, King’s
College London
Richard Siow is currently a Senior Lecturer in the Cardiovascular
Division, School of Medicine at King’s College London. He graduated
with a degree in Nutrition in 1993 and subsequently completed his
PhD research in the role of dietary antioxidants on vascular function in
1996, both at King’s College London. He continued his postdoctoral
research in the Centre for Cardiovascular Biology & Medicine at King’s
until 1998 when he moved to University of Cambridge as a research
associate in the Division of Cardiovascular Medicine to carry out
research on the mechanisms of reversing vascular remodelling by gene
transfer. In 2001 Richard was appointed to a tenured faculty position
in the Cardiovascular Division, School of Medicine at King’s College
London where his current research focuses on the regulation of vascular
endothelial and smooth muscle cells by reactive oxygen species, dietary
phytonutrients in relation to vascular nutrigenomics and ageing. Richard
is currently a member of the editorial board for Free Radical Research,
Frontiers in Nutigenomics and also Oxidative Medicine & Cellular
Longevity. He has been an active member of the Society for Free Radical
Research, the Physiological Society and the British Microcirculation
Society for over 12 years and now has established several industry linked
research collaborative projects.
Dr Asif Iqbal
The use of label-free electrical impedance sensing technologies to
investigate G-protein coupled receptor signalling & chemotaxis in both
primary murine macrophages & transfected cell lines
Post-Doc Research Scientist, University of Oxford
Inflammation is a central theme throughout my research, with particular
emphasis placed upon the anti-inflammatory mechanisms at play
in both innate and adaptive immune models of inflammation. My
doctoral training was carried out at the John Vane Science Centre,
William Harvey Research Institute, QMUL and focused on endogenous
galectin-1 as a regulator of inflammation. I am currently a postdoc at
the Sir William Dunn School of Pathology, University of Oxford in the
group led by Professor David R Greaves. My current interests focus on
the role chemokines play in monocyte and macrophage recruitment in
the context of atherosclerosis, a disease process that occurs in major
arteries causing angina, heart attack, stroke and peripheral arterial
disease. I have developed several techniques to visualise monocyte and
macrophage chemotaxis in real time, allowing us to begin studying the
role of different physiological mediators on macrophage chemotaxis, in
response to a range of chemoattractants.
Dr Patrick Kiely
Using real-time cell analysis to monitor the transformed phenotype in cancer
Lecturer & Principal Investigator of the Laboratory of Cellular &
Molecular Biology, University of Limerick
Pat Kiely has a BSc in Biomedical Science and a PhD in Biochemistry.
He is Principal Investigator of the Laboratory of Cellular and Molecular
Biology at the University of Limerick, Limerick, Ireland. Research
projects ongoing in his laboratory range from the most fundamental,
where the development of a better understanding of the molecular
mechanisms regulating cell migration is the goal, to the very applied,
where the identification of novel therapeutic targets and the design and
synthesis of novel materials and surfaces to study cell behavior is the
desired endpoint. Pat’s group use xCELLigence platforms to monitor cell
behavior in the normal and diseased state.
Mr Philip Sandom
Labcare – an effective & professional technical service partner for
Cambridge Bioscience
Managing Director, Labcare Service Ltd
Phil joined Genetic Research Instrumentation Ltd (GRI) in 1993 and
in 2007 was appointed Operations Director with responsibility for
manufacturing and technical service support. With the demise of GRI
in 2010 Phil, together with his business partner Mike Sewell bought the
assets of the service division from the administrators and commenced
trading as a fully independent business. During the three years + of
trading the business has seen consistent growth and fully established
in the Life Science and Biotech sectors as the ‘go to’ company for
competent and reliable third party technical service support.
9. Radisson Blu Hotel, London Stansted - Tuesday 24th June 2014
17
xCELLigence RTCA Cardio Instrument
Fail faster – Avoid launching the next drug with unforeseen cardiotoxic effects.
Evaluate compounds for hERG modulation.
Rule out cardiotoxic
compounds earlier in
drug development
Obtain physiologically
relevant data through
non-invasive, label-
free monitoring of
cardiomyocyte beating
Use a 96-well format to
analyze both acute and
long-term effects on a
cell population
Visit www.bioscience.co.uk/xcelligencecardio
or call 01223 316 855 to learn more.
Drug Beating Profile (after Addition of Drug)
Control
Domperidone
Droperidol
Clofilium
Chloroquine
Notes
10. ACEA xCELLigence User Group Meeting
18
Notes
Control
12.5 µM Etoposide
25 µM Etoposide
50 µM Etoposide
100 µM Etoposide
5
4
3
2
1
0
0 20 40 60 80
NormalizedCellIndex Time (hours)
Treatment
Seed
Cells
Monitor Cells in Real Time!
Obtain more information about your cells than ever before.
Acquire data that endpoint analysis alone could never
realize, and advance your cell-based research. Expand your
resources with the revolutionary xCELLigence System
from ACEA Biosciences.
Perform real-time, label-free cellular assays to:
Generate more physiologically relevant data.
Measure short-term and long-term cellular effects.
Continuously monitor cell responses without the
use of exogenous labels.
Determine optimal time points for endpoint assays.
Proven technology and application versatility
As shown in more than 500 peer-reviewed publications
Join the growing number of researchers using xCELLigence
System time-dependent cell response profiles (TCRPs)
(Figure 1) and flexible throughput options to advance
discovery in a broad range of applications.
Cell invasion and migration assays
Compound- and cell-mediated cytotoxicity
Cell adhesion and spreading
Cell viability, proliferation, and differentiation
Receptor-mediated signaling
Virus-mediated cytopathogenicity
Cardiotoxic compound effects
High-throughput screening
Continuous quality control of cells in culture
Find out more at
www.bioscience.co.uk/xcelligence
Figure 1: Continuous monitoring reveals cytotoxicity caused
by DNA damage. Etoposide is a DNA-damaging agent that
induces apoptosis at high concentrations, while at lower
concentrations it leads to S-Phase and/or G2 arrest.
RTCA SP Instrument RTCA DP Instrument RTCA MP Instrument RTCA HT Instrument RTCA Cardio Instrument
For life science research only.
Not for use in diagnostic procedures.
The xCELLigence System for
Real-Time Cellular Analysis
Discover What You’ve Been Missing
